Zobrazeno 1 - 10
of 48
pro vyhledávání: '"George, Blackledge"'
Publikováno v:
BJOG: An International Journal of Obstetrics and Gynaecology. 101:142-146
Objective: To study whether intervention debulking surgery improves survival in patients with advanced ovarian cancer who have bulky (> 2 cm) residual disease after primary surgery. Design: A prospective multicentre randomised study. Setting: Hospita
Publikováno v:
International Journal of Gynecological Cancer. 1:215-222
CA125 levels in peritoneal lavage fluid (PLF) has been evaluated as a tumor marker in EOC. PLF samples were obtained by performing peritoneal lavage with 1L 0.9% saline, usually via temporary percutaneous cannulae. The study group comprised 87 EOC an
Autor:
Rajiv Varma, George Blackledge
Publikováno v:
Current Opinion in ONCOLOGY. 2:881-884
Publikováno v:
Journal of Surgical Oncology. 45:14-19
From November 1981 to July 1985, 124 women with International Federation of Gynecology and Obstetrics (FIGO) stage III ovarian cancer were treated in prospective studies of surgery and chemotherapy in our institution. Patients with no macroscopic can
Autor:
Hideyuki, Akaza, Takashi, Tsuruo, Nagahiro, Saijo, Saburo, Sone, Seiji, Isonishi, Yasuo, Ohashi, Shinzaburo, Noguchi, Junichi, Kurebayashi, Yoshiyuki, Kakehi, Hideki, Ishikawa, George, Blackledge
Publikováno v:
Gan to kagaku ryoho. Cancerchemotherapy. 32(10)
The 12 th Oncology Forum discussed the progress and future strategy of cancer prevention in Japan. The National Cancer Center has established a research center for screening focusing on the most common six cancer, stomach, lung, liver, colon, breast
Autor:
Hideyuki, Akaza, Masayuki, Nakagawa, Takashi, Tsuruo, Nagahiro, Saijo, Saburo, Sone, Nobuyuki, Yamamoto, Yoshihiro, Kakeji, Seigo, Nakamura, Junichi, Kurebayashi, Seiji, Isonishi, Yasuo, Ohashi, George, Blackledge, James, Carmichael
Publikováno v:
Gan to kagaku ryoho. Cancerchemotherapy. 31(4)
Based on presentations on the basic concepts and scientific rationale of anti-angiogenic approaches to cancer therapy and the possible applications in the area of prostate cancer, gastrointestinal cancer, lung cancer and breast cancer it is easy to c
Autor:
Hideyuki, Akaza, Masahiro, Fukuoka, Atsushi, Ohtsu, Michiyuki, Usami, Tadashi, Ikeda, Keisuke, Aiba, Seiji, Isonishi, Yasuo, Ohashi, Nagahiro, Saijo, Saburo, Sone, Shigeru, Tsukagoshi, Takashi, Tsuruo, Masuhiro, Kato, Osamu, Mikami, Rui-Ping, Dong, Mikael, von Euler, George, Blackledge, Don, Stribling
Publikováno v:
Gan to kagaku ryoho. Cancerchemotherapy. 30(4)
Based on reviews of the Japanese clinical trial situation in lung cancer, gastric cancer, prostate cancer and breast cancer, it was clear that much progress has been made in short time. There are considerable differences between Japan and the West an
Autor:
Hideyuki, Akaza, Yasuo, Ohashi, Yasuhiro, Shimada, Tadashi, Ikeda, Nagahiro, Saijo, Seiji, Isonishi, Yoshihiko, Hirao, Takashi, Tsuruo, Shigeru, Tsukagoshi, Saburo, Sone, Seigo, Nakamura, Masuhiro, Kato, Osamu, Mikami, Mikael, von Euler, George, Blackledge, Bob, Milsted, Brent, Vose
Publikováno v:
Gan to kagaku ryoho. Cancerchemotherapy. 29(11)
Evidence Based Medicine (EBM) is a growing concept in Japan as it is elsewhere. Central to improving the use of EBM is generation of data through well conducted controlled clinical studies. There are many problems associated with conduct of clinical
Autor:
Hideyuki, Akaza, Keisuke, Aiba, Seiji, Isonishi, Tadashi, Ikeda, Yasuo, Ohashi, Koji, Kawai, Nagahiro, Saijo, Toshiaki, Saeki, Saburo, Sone, Shigeru, Tsukagoshi, Takashi, Tsuruo, Narikazu, Boku, Masuhiro, Kato, Osamu, Mikami, George, Blackledge, Don, Stribling
Publikováno v:
Gan to kagaku ryoho. Cancerchemotherapy. 29(2)
Based on short reviews of lung, gastric, colorectal, prostate, breast and ovarian cancer, there remain significant differences between Japan and the West in the therapeutic regimen for most cancers. Some of the differences are due to differences in s
Publikováno v:
Gynecologic oncology. 40(3)
Forty-eight patients with advanced epithelial ovarian cancer were treated with a twopart cytotoxic regimen consisting of three cycles of cisplatin-based induction therapy followed by five cycles of escalating doses of cyclophosphamide, all given at 3